D.1. TRACK–HD TRACKING PROGRESSION IN PREMANIFEST AND EARLY HUNTINGTON’S DISEASE

¹S Tabrizi, the TRACK–HD Investigators, ²D Craufurd, ³A Dürr, ¹N Fox, ⁴C Frost, ⁵S Hicks, ⁶T Illmann, ⁷H Johnson, ⁵C Kennard, ⁶GB Landwehrmeyer, ⁷D Langbehn. ¹Institute of Neurology, Queen Square, London WC1N 3BG, UK, ²University of Manchester, Oxford Road, Manchester M13 9PL, UK, ³Hospital Salpetriere, 47–83 Boulevard de l’Hôpital, 75651 Paris Cedex 13, France, ⁴London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, ⁵Imperial College London, South Kensington Campus, London SW7 2AZ, UK, ⁶University of Ulm, Oberer Eselsberg 45/1, 89081 Ulm, Germany, ⁷University of Iowa, Iowa City, Iowa, USA, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹University of Münster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany, ¹⁰Leiden University Medical Center, 2300 RC Leiden, The Netherlands, ¹¹Harvard, Massachusetts General Hospital, 02130 Charlestown, Massachusetts, USA, ¹²Monash University, Clayton Campus, Clayton, 3800 Victoria, Australia

TRACK–HD is a multicentre, multinational, prospective, observational biomarker study of premanifest and early Huntington’s disease (HD). The goal of the project is to contribute essential methodology that will provide unique insights into the neurobiology of premanifest and early HD and form the basis for neuroprotective trials in premanifest and early HD. TRACK–HD complements existing observational studies (Predict–HD, PHAROS, Registry and COHORT), sharing some features, but also having areas of unique emphasis, including extensive annual testing, implementation of multi-site 3T magnetic resonance imaging acquisition and novel assessment techniques. Premanifest subjects are stratified to focus on those close to motor onset. The use of a small number of sites allows flexibility for evaluating relatively complex and expensive techniques and dynamic modification of the study as promising new methodologies emerge. Here we give an update on recruitment and assessment to date. By the end of July all …